Severe septal panniculitis in a multiple sclerosis patient treated with interferon-beta

Area of Science:

• Dermatology
• Neurology
• Pharmacology

Background:

• Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
• Interferon beta-1b is a common disease-modifying therapy for MS, administered subcutaneously.
• Injection site reactions are known adverse effects of subcutaneous therapies.

Observation:

• A case of severe septal panniculitis is presented in an MS patient.
• The panniculitis manifested as a painful, indurated, and erythematous lesion.
• The lesion developed at the site of subcutaneous interferon beta-1b administration.

Findings:

• The patient experienced a significant inflammatory skin reaction at the injection site.
• Septal panniculitis, an inflammation of the subcutaneous fat, was diagnosed.
• The reaction was directly linked to the administration of interferon beta-1b.

Implications:

• This case underscores the importance of recognizing and managing injection site panniculitis in MS patients on interferon therapy.
• Awareness of this potential adverse event can guide clinical practice and patient counseling.
• Further investigation into the mechanisms of interferon-induced panniculitis may be warranted.